BR

BrightPath Biotherapeutics Co., Ltd.

A clinical-stage biopharma company developing cancer immunotherapies and cell therapies.

4594 | T

Overview

Corporate Details

ISIN(s):
JP3274140007
LEI:
Country:
Japan
Address:
川崎市川崎区殿町三丁目25番22号

Description

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's core technology is its iPS-NKT platform, a novel allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to produce large, homogeneous quantities of natural killer T (NKT) cells for cancer treatment. This proprietary approach is designed to overcome the natural scarcity of NKT cells, enabling the therapeutic application of their multifaceted anti-tumor effects. In addition to its cell therapy program, the company's development pipeline includes cancer peptide vaccines and immuno-modulating antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-21 07:30
有価証券届出書(組込方式)
Japanese ZIP 241.2 KB
2025-11-14 07:34
確認書
Japanese ZIP 8.9 KB
2025-11-14 07:34
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese ZIP 198.0 KB
2025-06-20 09:01
臨時報告書
Japanese ZIP 22.8 KB
2025-06-19 08:36
確認書
Japanese ZIP 8.9 KB
2025-06-19 08:32
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese ZIP 23.4 KB
2025-06-19 08:25
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese ZIP 933.5 KB
2024-11-08 07:35
確認書
Japanese ZIP 9.0 KB
2024-11-08 07:34
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese ZIP 224.9 KB
2024-06-21 09:07
訂正有価証券届出書(組込方式)
Japanese ZIP 254.0 KB
2024-06-21 08:34
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese ZIP 23.2 KB
2024-06-21 08:33
確認書
Japanese ZIP 9.0 KB
2024-06-21 08:32
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese ZIP 990.5 KB
2024-06-19 08:00
有価証券届出書(組込方式)
Japanese ZIP 513.9 KB
2024-02-09 07:12
確認書
Japanese ZIP 9.1 KB

Automate Your Workflow. Get a real-time feed of all BrightPath Biotherapeutics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BrightPath Biotherapeutics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BrightPath Biotherapeutics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO
ABINGDON HEALTH PLC Logo
A CDMO specializing in lateral flow assays, offering development to manufacturing services.
United Kingdom
ABDX
ABIONYX Pharma Logo
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
France
ABNX
ABIVAX Logo
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
France
ABVX
Abivax S.A. Logo
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
United States of America
ABVX
ABL Diagnostics Logo
Develops molecular diagnostic solutions for managing infectious diseases.
France
ABLD
Abliva Logo
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
Sweden
ABLI
AB Science Logo
Researches and develops protein kinase inhibitors for human and veterinary medicine.
France
AB
ABVC BIOPHARMA, INC. Logo
Develops botanical drugs and medical devices for oncology, ophthalmology, and CNS.
United States of America
ABVC
ACADIA PHARMACEUTICALS INC Logo
Biopharmaceutical company developing medicines for CNS disorders and rare diseases.
United States of America
ACAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.